Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.
G M Camilleri, M A Loriot, G Le Teuff...
https://pubmed.ncbi.nlm.nih.gov/42173726/Actively Recruiting
Led by UNICANCER · Updated on 2026-04-23
400
Participants Needed
41
Research Sites
143 weeks
Total Duration
Researchers are studying how to adjust the dose of fluoropyrimidine chemotherapy based on uracilemia levels in patients with DPD deficiency who have gastrointestinal cancers. This phase II multicenter trial aims to find the best dose reduction strategy to reduce side effects while treating digestive cancers. The main question is which dose reduction is needed for patients with this enzyme deficiency. Participants will receive chemotherapy with doses adjusted according to their uracilemia level. Patients with low uracilemia <16 ngmL will get the full dose, while those with higher levels will receive varying dose reductions or random assignments between 25% and 50% reductions depending on their uracilemia range. Treatments include the FOLFOX or CAPOX chemotherapy regimens, given in cycles every 2 to 3 weeks. During the study, participants will visit the clinic every 2 to 3 weeks for checkups and tests to monitor side effects and treatment response. Researchers will measure the occurrence of serious blood and gastrointestinal toxicities after two treatment cycles and track dose adjustments, toxicity, and survival outcomes over several months and years. The study involves close monitoring of health and treatment effects for up to three years, depending on cancer stage.
CONDITIONS
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
N
Nicolas DE SOUSA CARVALHO
L
Laure MONARD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
UNICANCER
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 3 months covering four treatment cycles
Participants receive fluoropyrimidine chemotherapy with dose adjustments based on their uracilemia levels using FOLFOX or CAPOX regimens.
Visits every 14 or 21 days depending on chemotherapy regimen cycle
Duration - Up to 3 years
Participants are followed to assess long-term outcomes including disease-free survival, overall survival, and progression-free survival.
Periodic follow-up visits over 3 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Have more questions? Get in touch with our team for quick support
G M Camilleri, M A Loriot, G Le Teuff...
https://pubmed.ncbi.nlm.nih.gov/42173726/UNICANCER
Lead Sponsor